Coronary atherosclerosis can regress with very intensive statin therapy

Ilke Sipahi; Stephen J. Nicholls; E. Murat Tuzcu; Steven E. Nissen

doi:10.3949/ccjm.73.10.937

Coronary atherosclerosis can regress with very intensive statin therapy

Ilke Sipahi, Stephen J. Nicholls, E. Murat Tuzcu, Steven E. Nissen

Research output: Contribution to journal › Article › Research › peer-review

45 Citations (Scopus)

Abstract

The ASTEROID trial (JAMA 2006; 295:1556-1565) showed that very intensive statin therapy with rosuvastatin 40 mg once daily results in highly significant regression of coronary atherosclerosis as assessed by serial intravascular ultrasonography (IVUS). The mean low-density lipoprotein cholesterol (LDL-C) level achieved with this regimen was 61 mg/dL, and the mean high-density lipoprotein cholesterol (HDL-C) level increased by 15%. While the merits of concomitant LDL-C-lowering and HDL-C-raising therapies remain to be determined, the results of the ASTEROID and other recent trials suggest that the optimal strategy for lipid-lowering in patients with coronary artery disease is to try for the lowest LDL-C level that can be attained without adverse effects.

Original language	English
Pages (from-to)	937-944
Number of pages	8
Journal	Cleveland Clinic Journal of Medicine
Volume	73
Issue number	10
DOIs	https://doi.org/10.3949/ccjm.73.10.937
Publication status	Published - 1 Jan 2006
Externally published	Yes

Access to Document

10.3949/ccjm.73.10.937

Cite this

@article{5e153266c0474f44adaccfdeb98769e9,

title = "Coronary atherosclerosis can regress with very intensive statin therapy",

abstract = "The ASTEROID trial (JAMA 2006; 295:1556-1565) showed that very intensive statin therapy with rosuvastatin 40 mg once daily results in highly significant regression of coronary atherosclerosis as assessed by serial intravascular ultrasonography (IVUS). The mean low-density lipoprotein cholesterol (LDL-C) level achieved with this regimen was 61 mg/dL, and the mean high-density lipoprotein cholesterol (HDL-C) level increased by 15%. While the merits of concomitant LDL-C-lowering and HDL-C-raising therapies remain to be determined, the results of the ASTEROID and other recent trials suggest that the optimal strategy for lipid-lowering in patients with coronary artery disease is to try for the lowest LDL-C level that can be attained without adverse effects.",

author = "Ilke Sipahi and Nicholls, {Stephen J.} and Tuzcu, {E. Murat} and Nissen, {Steven E.}",

year = "2006",

month = jan,

day = "1",

doi = "10.3949/ccjm.73.10.937",

language = "English",

volume = "73",

pages = "937--944",

journal = "Cleveland Clinic Journal of Medicine",

issn = "0891-1150",

publisher = "Cleveland Clinic Educational Foundation",

number = "10",

}

TY - JOUR

T1 - Coronary atherosclerosis can regress with very intensive statin therapy

AU - Sipahi, Ilke

AU - Nicholls, Stephen J.

AU - Tuzcu, E. Murat

AU - Nissen, Steven E.

PY - 2006/1/1

Y1 - 2006/1/1

N2 - The ASTEROID trial (JAMA 2006; 295:1556-1565) showed that very intensive statin therapy with rosuvastatin 40 mg once daily results in highly significant regression of coronary atherosclerosis as assessed by serial intravascular ultrasonography (IVUS). The mean low-density lipoprotein cholesterol (LDL-C) level achieved with this regimen was 61 mg/dL, and the mean high-density lipoprotein cholesterol (HDL-C) level increased by 15%. While the merits of concomitant LDL-C-lowering and HDL-C-raising therapies remain to be determined, the results of the ASTEROID and other recent trials suggest that the optimal strategy for lipid-lowering in patients with coronary artery disease is to try for the lowest LDL-C level that can be attained without adverse effects.

AB - The ASTEROID trial (JAMA 2006; 295:1556-1565) showed that very intensive statin therapy with rosuvastatin 40 mg once daily results in highly significant regression of coronary atherosclerosis as assessed by serial intravascular ultrasonography (IVUS). The mean low-density lipoprotein cholesterol (LDL-C) level achieved with this regimen was 61 mg/dL, and the mean high-density lipoprotein cholesterol (HDL-C) level increased by 15%. While the merits of concomitant LDL-C-lowering and HDL-C-raising therapies remain to be determined, the results of the ASTEROID and other recent trials suggest that the optimal strategy for lipid-lowering in patients with coronary artery disease is to try for the lowest LDL-C level that can be attained without adverse effects.

UR - http://www.scopus.com/inward/record.url?scp=33750052563&partnerID=8YFLogxK

U2 - 10.3949/ccjm.73.10.937

DO - 10.3949/ccjm.73.10.937

M3 - Article

C2 - 17044319

AN - SCOPUS:33750052563

SN - 0891-1150

VL - 73

SP - 937

EP - 944

JO - Cleveland Clinic Journal of Medicine

JF - Cleveland Clinic Journal of Medicine

IS - 10

ER -

Coronary atherosclerosis can regress with very intensive statin therapy

Abstract

Access to Document

Other files and links

Cite this